AngioDynamics, Inc.  

(Public, NASDAQ:ANGO)   Watch this stock  
Find more results for ANGO
-0.08 (-0.46%)
Nov 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.29 - 17.67
52 week 14.80 - 18.85
Open 17.43
Vol / Avg. 0.00/157,145.00
Mkt cap 636.65M
P/E 181.36
Div/yield     -
EPS 0.10
Shares 36.72M
Beta 1.05
Inst. own 97%
Jan 4, 2018
Q2 2018 AngioDynamics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Oct 17, 2017
AngioDynamics Inc Annual Shareholders Meeting
Sep 28, 2017
Q1 2018 AngioDynamics Inc Earnings Release
Sep 28, 2017
Q1 2018 AngioDynamics Inc Earnings Call - Webcast
Sep 25, 2017
AngioDynamics Inc at Cantor Fitzgerald Global Healthcare Conference - Webcast
Sep 11, 2017
AngioDynamics Inc at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Aug '17) 2017
Net profit margin -0.04% 1.43%
Operating margin 0.16% 3.71%
EBITD margin - 14.31%
Return on average assets -0.02% 0.70%
Return on average equity -0.03% 0.98%
Employees 1,250 -
CDP Score - -


14 Plaza Dr
LATHAM, NY 12110-2166
United States - Map
+1-518-7981215 (Phone)
+1-518-7951401 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company's Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company's BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.

Officers and directors

Howard W. Donnelly Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
James C. Clemmer President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Michael C. Greiner Chief Financial Officer, Executive Vice President, IR Contact Officer
Age: 44
Bio & Compensation  - Reuters
Robert A. Simpson Senior Vice President and General Manager, Peripheral Vascular
Age: 45
Bio & Compensation  - Reuters
Heather J. Daniels-Cariveau Senior Vice President of Human Resources
Age: 43
Bio & Compensation  - Reuters
Gary Barrett Senior Vice President,Quality and Regulatory Affairs
Age: 47
Bio & Compensation  - Reuters
Chad T. Campbell Senior Vice President and General Manager, Vascular Access
Age: 46
Bio & Compensation  - Reuters
Benjamin Davis Senior Vice President, Business Development
Age: 52
Bio & Compensation  - Reuters
Barbara A. Kucharczyk Senior Vice President-Global Operations
Age: 44
Bio & Compensation  - Reuters
Warren G. Nighan Senior Vice President-Senior Vice President Quality & Regulatory Affairs
Age: 48
Bio & Compensation  - Reuters